EUVIMEDEUVIMED entdecken
Crossref

The COVID‐19 vaccine ChAdOx1 is opsonized by anti‐vector antibodies that activate complement and promote viral vector phagocytosis

Eija Nissilä iD, Leo Starck iD, Elias Aho, Erika Venerandi, Pinja Jalkanen, Katarzyna Leskinen, Pavel Uvarov, Päivi Saavalainen, Ilkka Julkunen, Juha Kotimaa, Karita Haapasalo, Seppo Meri

Scandinavian Journal of Immunology · 2025

DOI: 10.1111/sji.70000 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Scandinavian Journal of Immunology, 2025. Verfasst von Eija Nissilä und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Bacteriology and Immunology, Medicum, University of Helsinki, Helsinki, Finland. Hauptthemen laut MEDLINE: Phagocytosis, SARS-CoV-2, COVID-19, COVID-19 Vaccines. Die Arbeit nennt 48 Literaturangaben. Gefördert von: Sigrid Juséliuksen Säätiö, Helsingin ja Uudenmaan Sairaanhoitopiiri, Academy of Finland.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The ChAdOx1 nCoV‐19 vaccine has been in large‐scale use during the COVID‐19 pandemic. Limited efficacy compared to mRNA vaccines and certain potential side effects raise the question of whether anti‐adenoviral vector antibodies influence immune responses against the vaccine. Complement activation by ChAdOx1 and leukocyte phagocytosis of ChAdOx1 in vitro were studied. Plasma IgG levels against ChAdOx1 and human adenovirus 2 (hAdV2) hexon protein were determined ( n = 20) and IgGs from high‐ and low‐titre plasmas were isolated ( n = 3). Complement activation was measured as cleavage of C3 by immunoblotting and generation of C3a and sC5b‐9 by ELISA. pHrodo‐labelled ChAdOx1 was opsonized with complement and IgG, and phagocytosis by isolated blood PMNs in vitro was studied by flow cytometry. The transcriptomic profile of PMN cells exposed to ChAdOx1 was analysed by RNA‐seq. ChAdOx1 activated the classical complement pathway in an anti‐adenovirus antibody‐dependent manner. Generation of the terminal complement complex sC5b‐9 in individual sera correlated with anti‐hAdV2 hexon and anti‐ChAdOx1 IgG levels. Phagocytosis of ChAdOx1 also correlated significantly with anti‐hAdV2 hexon IgG, anti‐ChAdOx1 IgG and serum sC5b‐9 levels. High‐titre anti‐hAdv2 hexon IgG increased phagocytosis in the presence of normal serum. Anti‐vector antibodies induced rapid complement activation and promoted phagocytosis of the ChAdOx1 vaccine by neutrophils. Moreover, transcriptomic analysis revealed upregulation of complement‐related genes induced by the ChAdOx1 vaccine in vitro. Anti‐adenovirus vector antibodies and complement activation may thus influence the efficacy of the ChAdOx1 vaccine against SARS‐CoV‐2 and be also involved in vaccine‐related side effects.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PhagocytosisSARS-CoV-2COVID-19COVID-19 VaccinesAntibodies, ViralComplement ActivationHumansChAdOx1 nCoV-19Immunoglobulin GNeutrophilsOpsonizationGenetic VectorsMaleFemaleAdultMiddle Aged

Stichwörter der Autor:innen

ChAdOx1adenovirus vectorantibodiescomplementphagocytosis

Substanzen

ChAdOx1 nCoV-19COVID-19 VaccinesAntibodies, ViralImmunoglobulin G

Autor:innen und Institutionen

  • Department of Bacteriology and Immunology, Medicum, University of Helsinki, Helsinki, Finland.
  • Human Microbiome Research Program University of Helsinki, Helsinki, Finland.
  • Translational Immunology Research Program, University of Helsinki, Helsinki, Finland.
  • Department of Biomedical Sciences, Humanitas University, Milan, Italy.
  • Institute of Biomedicine, University of Turku, Turku, Finland.
  • Folkhälsan Research Center, Helsinki, Finland.

ORCID-Profile: Eija Nissilä, Leo Starck

Förderung

  • Sigrid Juséliuksen Säätiö
  • Helsingin ja Uudenmaan Sairaanhoitopiiri
  • Academy of Finland
  • Research Council of Finland

Zitieren

APA

Nissilä, E., Starck, L., Aho, E., Venerandi, E., Jalkanen, P., Leskinen, K., Uvarov, P., Saavalainen, P., Julkunen, I., Kotimaa, J., Haapasalo, K., & Meri, S. (2025). The COVID‐19 vaccine ChAdOx1 is opsonized by anti‐vector antibodies that activate complement and promote viral vector phagocytosis. Scandinavian Journal of Immunology. https://doi.org/10.1111/sji.70000

Vancouver

Nissilä E, Starck L, Aho E, Venerandi E, Jalkanen P, Leskinen K, et al. The COVID‐19 vaccine ChAdOx1 is opsonized by anti‐vector antibodies that activate complement and promote viral vector phagocytosis. Scandinavian Journal of Immunology. 2025. doi:10.1111/sji.70000

BibTeX
@article{Nissil2025,
  author = {Nissilä, Eija and Starck, Leo and Aho, Elias and Venerandi, Erika and Jalkanen, Pinja and Leskinen, Katarzyna and Uvarov, Pavel and Saavalainen, Päivi and Julkunen, Ilkka and Kotimaa, Juha and Haapasalo, Karita and Meri, Seppo},
  title = {The COVID‐19 vaccine ChAdOx1 is opsonized by anti‐vector antibodies that activate complement and promote viral vector phagocytosis},
  journal = {Scandinavian Journal of Immunology},
  year = {2025},
  doi = {10.1111/sji.70000}
}
Kostenlos starten →